4.4 Article

Inflammatory Properties and Adjuvant Potential of Synthetic Glycolipids Homologous to Mycolate Esters of the Cell Wall of Mycobacterium tuberculosis

Journal

JOURNAL OF INNATE IMMUNITY
Volume 9, Issue 2, Pages 162-180

Publisher

KARGER
DOI: 10.1159/000450955

Keywords

Mycobacterium tuberculosis; Glycolipids; Trehalose dimycolate; Trehalose monomycolate; Glucose monomycolate; Arabinose monomycolate; Inflammasome; Adjuvant

Categories

Funding

  1. Interuniversity Attraction Pole Programme [IAP 7/32]
  2. TBVAC [H2020-PHC-643381]
  3. Ministry of Higher Education and Scientific Research, Kurdistan Region, Iraq, for the award of a PhD studentship
  4. Deutsche Forschungsgemeinschaft [SFB 796/B6]

Ask authors/readers for more resources

The cell wall of mycobacteria is characterised by glycolipids composed of different classes of mycolic acids (MAs; alpha-, keto-, and methoxy-) and sugars (trehalose, glucose, and arabinose). Studies using mutant Mtb strains have shown that the structure of MAs influences the inflammatory potential of these glycolipids. As mutant Mtb strains possess a complex mixture of glycolipids, we analysed the inflammatory potential of single classes of mycolate esters of the Mtb cell wall using 38 different synthetic analogues. Our results show that synthetic trehalose dimycolate (TDM) and treha-lose, glucose, and arabinose monomycolates (TMM, GMM, and AraMM) activate bone marrow-derived dendritic cells in terms of the production of pro-inflammatory cytokines (IL-6 and TNF-alpha) and reactive oxygen species, upregulation of costimulatory molecules, and activation of NLRP3 inflamma-some by a mechanism dependent on Mincle. These findings demonstrate that Mincle receptor can also recognise pentose esters and seem to contradict the hypothesis that production of GMM is an escape mechanism used by pathogenic mycobacteria to avoid recognition by the innate immune system. Finally, our experiments indicate that TMM and GMM, as well as TDM, can promote Th1 and Th17 responses in mice in an OVA immunisation model, and that further analysis of their potential as novel adjuvants for subunit vaccines is warranted. (C) 2016 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available